{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:46:46Z","timestamp":1778600806367,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Patients with Triple-negative breast cancer (TNBC) face a poor prognosis and limited therapeutic options. Current data on eribulin usage to treat TNBC is scarce. Therefore, we sought to compare the feasibility and tolerability of eribulin-based regimens with other chemotherapy regimens in patients with TNBC.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> This retrospective study was conducted at Fujian Medical University Cancer Hospital and included 159 patients with TNBC enrolled between October 2011 and January 2023. Patients underwent treatment with eribulin-based and other chemotherapy regimens. The study\u2019s primary endpoints were progression-free survival (PFS) and overall survival (OS), while its secondary endpoint was objective response rate (ORR), disease control rate (DCR), and safety. Tumour response was assessed using RECIST V.1.1 criteria.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of the 159 participants in the study, 42 individuals (26.4%) received treatment with eribulin, whereas 117 participants (73.6%) were administered alternative chemotherapy regimens, which included nab-paclitaxel-based therapy (n = 45) and platinum-based therapy (n = 51). The follow-up period for all patients ended on 31 December 2022, and the median follow-up time was 18.3 months (range:0.7\u201327.5). Following propensity score matching (PSM), eribulin-based treatment resulted in longer median progression-free survival compared to platinum-based (hazard ratio (HR) = 0.41, <jats:italic>p<\/jats:italic> = 0.006), nab-paclitaxel-based (hazard ratio = 0.36, <jats:italic>p<\/jats:italic> = 0.001) and other chemotherapy (HR = 0.39, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Also, eribulin induced a remarkable prolongation of the median overall survival duration in all three comparative groups. The group receiving eribulin treatment showed significantly reduced incidences of any grade of anaemia, peripheral neuropathy, nausea and vomiting, and hair loss compared to other chemotherapy groups.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> For the salvage treatment of advanced TNBC, treatment with eribulin produced longer median PFS and OS than other chemotherapy regimens, with a well-tolerated safety profile. Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted.<\/jats:p>","DOI":"10.3389\/fcell.2024.1313610","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T05:25:00Z","timestamp":1708579500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Weiwei","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangkun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nani","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanzhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2217\/fon-2018-0324","article-title":"Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study","volume":"15","author":"Barni","year":"2019","journal-title":"Future Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN clinical practice guidelines in Oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/s1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s10637-019-00890-5","article-title":"Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting","volume":"38","author":"Inoue","year":"2020","journal-title":"Invest. New Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1200\/jco.2014.57.6660","article-title":"TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/jco.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1200\/jco.2018.79.2028","article-title":"Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s12325-020-01613-6","article-title":"Effectiveness of eribulin in metastatic breast cancer: 10 Years of real-world clinical experience in the United States","volume":"38","author":"Mougalian","year":"2021","journal-title":"Adv. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10549-013-2447-8","article-title":"Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis","volume":"138","author":"O'Shaughnessy","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejca.2017.10.002","article-title":"Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer","volume":"86","author":"Park","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/md17060329","article-title":"Marine-derived anticancer agents: clinical benefits, innovative mechanisms, and new targets","volume":"17","author":"Pereira","year":"2019","journal-title":"Mar. Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/14740338.2019.1608946","article-title":"The safety of eribulin for the treatment of metastatic breast cancer","volume":"18","author":"Perez-Garcia","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12282-017-0826-4","article-title":"Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine","volume":"25","author":"Pivot","year":"2018","journal-title":"Breast Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.3390\/cancers14184532","article-title":"Systematic analysis of genetic and pathway determinants of eribulin sensitivity across 100 human cancer cell lines from the cancer cell line encyclopedia (CCLE)","volume":"14","author":"Sachdev","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4137\/bcbcr.S39615","article-title":"Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer","volume":"10","author":"Twelves","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1016\/j.bioactmat.2021.04.028","article-title":"Biomaterials from the sea: future building blocks for biomedical applications","volume":"6","author":"Wan","year":"2021","journal-title":"Bioact. Mater"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","article-title":"A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/annonc\/mdy201","article-title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial","volume":"29","author":"Yardley","year":"2018","journal-title":"Ann. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/bctt.S231298","article-title":"Clinical utility of eribulin mesylate in the treatment of breast cancer: a Chinese perspective","volume":"13","author":"Yuan","year":"2021","journal-title":"Breast Cancer (Dove Med. Press)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncologist"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1313610\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:56:20Z","timestamp":1709135780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1313610\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":27,"alternative-id":["10.3389\/fcell.2024.1313610"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1313610","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"article-number":"1313610"}}